The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology

Xavier Matias-Guiu1 · Giorgio Stanta2 · Fátima Carneiro3 · Ales Ryska4 · Gerald Hoefler5 · Holger Moch6 · on behalf of the European Society of Pathology (ESP)

Received: 30 October 2019 / Revised: 10 January 2020 / Accepted: 14 January 2020 / Published online: 2 March 2020
© The Author(s) 2020

Abstract
Molecular pathology is an essential part of pathology complementing conventional morphological tools to obtain a correct integrated diagnosis with appropriate assessment of prognosis and prediction of response to therapy, particularly in cancer. There is a concern about the situation of molecular pathology in some areas of Europe, namely, regarding the central role of pathologists in assessing somatic genomic alterations in cancer. In some countries, there are attempts that other laboratory medicine specialists perform the molecular analysis of somatic alterations in cancer, particularly now when next generation sequencing (NGS) is incorporated into clinical practice. In this scenario, pathologists may play just the role of “tissue providers,” and other specialists may take the lead in molecular analysis. Geneticists and laboratory medicine specialists have all background and skills to perform genetic analysis of germline alterations in hereditary disorders, including familial forms of cancers. However, interpretation of somatic alterations of cancer belongs to the specific scientific domain of pathology. Pathologists are necessary to guarantee the quality of the results, for several reasons: (1) The identified molecular alterations should be interpreted in the appropriate morphologic context, since most of them are context-specific; (2) pre-analytical issues must be taken into consideration; (3) it is crucial to check the proportion of tumor cells in the sample subjected to analysis and presence of inflammatory infiltrate and necrosis should be monitored; and (4) the role of pathologists is crucial to select the most appropriate methods and to control the turnaround time in which the molecular results are delivered in the context of an integrated diagnosis.

Obviously, there is the possibility of having core facilities for NGS in a hospital to perform the sequence analysis that are open to other specialties (microbiologists, geneticists), but also in this scenario, pathologists should have the lead in assessing somatic alterations of cancer. In this article, we emphasize the importance of interpreting somatic molecular alterations of the tumors in the context of morphology. In this Position Paper of the European Society of Pathology, we strongly support a central role of pathology departments in the process of analysis and interpretation of somatic molecular alterations in cancer.

Keywords Molecular pathology · Pathology · Pre-analytical issues · Integrative pathology
Cancer as a complex genetic and epigenetic disease

Cancer is a complex disease. Hereditary and environmental factors are important in its development. Cancer results from accumulation of genetic and epigenetic alterations in cells [1], under the influence of the immune system and the non-neoplastic microenvironment, which is usually tumor-type specific. Cancer cells have important interactions with non-cancer host cell populations, such as fibroblasts, vessels, or inflammatory cells [2].

Every type of cancer has its own molecular profile. Even more, each individual cancer in a particular patient has its unique repertoire of molecular abnormalities [3]. With the exception of some types of tumors, it is virtually impossible to find two tumors from two different patients, even from the same organ, having the same genetic and epigenetic background. Thus, from the biological viewpoint, each tumor represents a unique scenario resulting from a sequence of individual molecular changes. We know today that the morphologic appearance of the tumors reflects the genetic and epigenetic changes present in tumor cells. Microscopy has been crucial in recognizing biologically distinct entities with specific molecular features, and, on the other hand, molecular profiling has allowed identifying new tumor types that turned out to have specific microscopic features.

Role of pathology in the diagnosis of cancer

For many years, cancer has been diagnosed on the basis of its microscopic appearance. Several decades ago, identification of proteins by immunohistochemistry became an important tool in cancer diagnosis [4]. Later on, identification of single gene alterations (mutations, gene fusions, amplifications, by PCR-based mutation analysis, or FISH) was incorporated into pathological report and is used today as a tool to help in diagnosis, prognosis, and prediction in response to treatment. Over the years, WHO classifications of tumors have transformed from exclusive morphologic criteria into integrated morphologic-molecular schemes. Novel technologies like NGS are providing more information to understand the molecular profile of each particular tumor. Bioinformatic support is an essential tool for the analysis of large-scale molecular datasets. Microscopic appearance, nevertheless, provides the framework in which molecular analysis should be interpreted.

Pathology is the medical discipline responsible for the diagnosis of diseases based on the morphological appearance under the microscope of tissue or cytological samples. Cancer is one of the areas where the progress in pathology is most dynamic and significant. The role of pathologists in diagnosis of cancer, as well as assessment of prognostic and predictive factors, is crucial. The task for pathologists is not only the evaluation of the gross appearance of the lesion together with microscopic assessment of neoplastic tissue. To guarantee high reliability of pathological diagnosis, the so-called pre-analytical conditions (handling of the material before the testing itself) must be controlled. Another crucial issue is the appropriate sampling of most relevant diagnostic areas, as well as selection of the most informative tumor areas for additional ancillary techniques [5, 6].

Generally speaking, a patient does not have a proven cancer diagnosis, until a pathologist establishes such diagnosis in a histologic or cytologic specimen. Obviously, there are few exceptions to this statement, for some malignancies and disseminated tumors, in which obtaining a tissue sample may be too risky for the patient.

Pathologists are not laboratory specialists who identify, quantify, and report molecules from blood or other biological samples. We are medical specialists interpreting the microscopic appearance of the tumor in the setting of the molecular, clinical, and imaging features. Occasionally, similar microscopic pictures can lead to different diagnoses, depending on age, tumor site, or clinical scenario.

Interpretation by pathologists is also essential for correct interpretation of molecular research data resulting from the analysis of tissues and cells [7, 8]. The anomaly of interpreting and reporting research pathologic features in human and animal models without the appropriate expertise in pathology has led to inadequate interpretation and occasional retraction of erroneous results, even in highly prestigious peer-review journals [9]. The term “pathology by yourself” or “do it yourself” has been used to designate this incorrect way of interpreting molecular data, in which researchers perform their own pathologic analysis, lacking appropriate training in pathology [10]. It would be inadmissible to accept similar practice when providing pathologic diagnosis in patients’ tissue samples (biopsies and/or surgical specimens), potentially resulting in inappropriate or even entirely wrong decisions in patients’ care.

Germline molecular alterations in cancer

The genetic alterations that are detected in cancer tissues can be germline or somatic. Cancer-related germline genetic abnormalities occur in the setting of clinical situations with an increased risk for the development of cancer. Familial cancer syndromes are the paradigmatic examples. Germline alterations are important for tumor development, and their identification may be important for prognosis or even for prediction of response to certain types of systemic anticancer treatment. Germline alterations are detected in tumor tissue but also in normal non-neoplastic tissues from cancer patients. Peripheral blood is the most frequently used biological material for identification of germline changes. Management of DNA and
RNA from peripheral blood is less challenging than that obtained from tumor tissue, as the nucleic acids in the blood are less negatively influenced by pre-analytical conditions.

Identification and interpretation of germline alterations in cancer do not usually require integration of the results in the context of morphological features of the tumors. It may be perfectly performed by geneticists, who have the appropriate expertise, including skills to classify the identified variations regarding their impact and distinguish between pathogenic changes from those that are not. Bioinformatic support is essential. Since the tumors occurring in the setting of familial cancer syndromes may sometimes have specific morphologic features, it is desirable to have pathologists as part of the multidisciplinary teams interpreting results of germline molecular testing and establishing screening or surveillance strategies. However, it does not seem necessary that pathologists have the lead in these clinical strategies.

Occasionally, analysis of somatic mutations may lead to identification of a genetic change that may be suspicious to be in fact a germline alteration. Additional conventional germline mutation analysis (from peripheral blood) in close collaboration with clinical geneticist may be mandatory to confirm the germline nature of these genetic variants.

Evidence of BRCA1/2 mutations or microsatellite instability (Lynch syndrome) should be noted in the pathology report with a recommendation that clinical geneticists have to be involved to perform genetic counseling of the patient with this family.

**Importance of interpreting somatic alterations in cancer in the appropriate morphological context**

The scenario of somatic genomic alterations of cancer is different from that of the germline ones. The clinical and pathologic contexts are important. Integration of molecular results with microscopic features is necessary. There are tissue-specific differences in tumorigenesis and the organization of individual oncogenic signaling pathways. There are many examples of somatic alterations (BRAF, KIT) that have different significance depending on tumor type [11]. There are many evidences showing that the genomic landscape and the relevance of activated signaling pathways differ with respect to tumor type and organ location [12]. Different cells and tissues have important differences in their response to oncogenic driver mutations [13, 14], and cancer drivers may have different roles in different cell types or stages of differentiation. Recent basket trials provide evidence that the response to a molecular alteration-specific anticancer drug often depends on the pathologic cancer type as well as on the tissue of origin [11]. The context-specific preservation of feedback explains why and how oncogene addiction maintains a certain level of signaling output and counteracting intrinsic feedback inhibition [15], depending on cell type.

Interpretation of somatic alterations of cancer should be therefore performed in the setting of pathology departments. In this regard, it is necessary that pathology departments incorporate specialists with strong molecular expertise (biochemists, molecular biologists) as well as bioinformaticians, who should be integrated as full-fledged staff members. This is currently the situation in a significant proportion of tertiary hospitals across Europe; however, in some areas, there are administrative difficulties for an efficient incorporation.

Incorporation of NGS into clinical practice is having a tremendous impact in management of cancer patients [16]. In some scenarios, single-gene approaches seem to be still cost-effective, but in steadily growing proportion of clinical situations, there is a need for multigene approach, i.e., analyzing sets of multiple clinically relevant genes at the same time. This strategy is saving the tissue, which is often limited, increasing cost-efficiency, and reducing turnaround time of response. It is the responsibility of pathologist to select, on the basis of morphologic findings, the markers which should be tested and to guarantee the choice of appropriate methods as well as optimal use of the limited tissue sample. While NGS is frequently used for identification of germline alterations in cancer, because a high number of simultaneously analyzed genes are usually necessary, its use to identify somatic abnormalities is also becoming more accessible.

In some centers, NGS equipment is based in pathology departments. In other centers, NGS facility is shared in central core facilities, available to several different specialties. In some of these centers, pathologists have access to NGS equipment and perform somatic molecular interpretation followed by delivery of an integrated pathologic report. In other centers, NGS is performed by other specialists, and pathologists are only requested to simply provide tissue samples, without too much interaction, and insufficient involvement in reporting the results. We are strongly convinced that this role of just “tissue providers” would be totally inappropriate, carrying important risks of incorrect interpretation of molecular findings outside of the tissue context, and might be thus potentially detrimental to patient safety.

Sometimes, hospital administrators do not consider the abovementioned conditions and take unfortunate decisions allowing molecular testing and interpretation of cancer somatic alterations in facilities, outside pathology departments, without guaranteeing integration into the appropriate pathologic context. These wrong decisions are usually based on economical or organizational parameters, not supported by scientific evidence.

Another important fact which must be taken into consideration is the issue of tumor heterogeneity. There is increasing evidence that tumors are composed of subpopulations of cells with distinct genetic alterations [17, 18]. Tumor heterogeneity
has its consequences often also at the microscopic level. With
the advent of NGS techniques, the occurrence and extent of
intra-tumor heterogeneity is becoming acknowledged and cor-
relates many times with different microscopic features. Spatial
and temporal heterogeneity may permit the tumor to adapt to
variations in tumor microenvironment. Comparison of the so-
matic mutations of primary tumors and metastasis or in tumor
areas with different histological patterns indicates that somatic
gene alterations may vary substantially. It has been shown that
tumor heterogeneity can be a challenge for evaluating the
suitability of individual targeted therapies, since abnormalities
in target genes can be heterogeneous distributed in different
subpopulations of an individual tumor. Evaluation of tumor
heterogeneity at the microscopic level in conjunction with its
tumor-associated microenvironment is necessary for the opti-
mal selection of a tissue block for molecular analysis; this
step, seemingly simple, may have a crucial impact on
assessing correctly prognosis or prediction of response to
treatment.

As mentioned before, the clinical and microscopic context
is essential to interpret appropriately the results. This is rele-
vant not only for tumor morphology but also to interpret the
role of non-cancer microenvironment in conjunction with mo-
lecular data. However, it is important to emphasize that any
molecular test is just one small part of the entire complex
pathologic diagnosis. Traditional pathological features, such
as gross findings, tumor stage, histological type, and grade
based on microscopic evaluation and molecular findings,
should be therefore integrated in a combined pathologic re-
port. Moreover, digital pathology, which is recently being im-
plemented in many pathology departments, may become an
additional useful tool to integrate molecular results in the ap-
propriate pathological context [19]. Advances in digital pa-
thology will help in implementing algorithms of artificial in-
telligence, as an additional tool for integrating all information
retrieved from a cancer tissue specimen [20].

Indications for molecular analysis in pathology have
changed over the last decade. Molecular pathology was ini-
tially performed virtually exclusively for diagnostic purposes
in hematologic disorders and solid tumors, and pathologists
were the solely responsible for deciding when and which spe-
cific test should be performed in a particular case. Nowadays,
however, a significant proportion of the molecular tests are
performed for predictive purposes, to identify subsets of can-
cer patients who will have higher probability to respond to
certain anticancer treatment. This has led to a change of roles,
and the tests are now frequently requested by clinician. Under
such circumstances, a close interaction between oncologists
and pathologists is necessary, with efficient workflow and
decision-making strategies, in which Molecular Tumor
Boards are excellent scenarios. Nowadays, many pathology
departments organize Molecular Tumor Boards, involving
molecular biologists, bioinformaticians, and oncologists, to
discuss the relevance of NGS findings for targeted therapies
in different organ tumors (lung, breast, urological cancers)
together. These Molecular Tumor Boards represent ideal plat-
forms for a comprehensive discussion of all aspects of molec-
ular diagnostics and the consequences for targeted therapies. It
should be emphasized, however, that pathologist should play a
role in the decision about the most appropriate molecular ass-
ay that must be performed, particularly for cancer diagnosis
(Fig. 1).

The number of molecular tests that are incorporated to reg-
ular testing of tissues is constantly growing, in concordance
with development of novel targeted therapies requiring new
predictive biomarkers [21]. In this scenario, pharmaceutical
companies involved in the development of innovative treat-
ment are becoming new actors, and their important role has to
be taken into account. However, this is a two-side process.
Recent experience from development of new checkpoint in-
hibitors clearly demonstrates that pathologists should be in-
volved also in the planning of new clinical trials, regarding
eligibility, stratification, quality control, and particularly pa-
rameters for evaluation of response to therapy, and establish-
ment of criteria for scoring predictive biomarkers. Only so we
can eliminate (or at least minimize) later complications and
issues during the implementation of testing after the drug
approval.

Currently, a new paradigm for cancer care is emerging,
where treatments are identified based on the specific genetic
profile of an individual’s tumor, regardless of where it first
originated. Pathologists diagnose tumors based on a specific
histological type and the organ of origin. However, organiza-
tions such as the American Food and Drug Administration
(FDA) have recently shown a willingness to accept novel trial
designs—such as basket studies, which enroll patients for
treatments based on the biology of their tumor, not their tumor
type. These “tumor-agnostic” agents target gene alterations
thought to drive tumor growth regardless of cancer histology.
“Tumor-agnostic” therapies are based on identification of mi-
crosatellite instability or high tumor mutational burden for
immuno-oncological therapies [22]. Other examples include
TRK inhibitors, showing clinically meaningful responses in
patients with NTRK fusions. NTRK gene fusions are present
in a broad range of more than 20 different tumor types, in-
cluding those of the head and neck, salivary gland, bladder,
and lung [23, 24]. It is the task of pathologists to proof this
controversial concept and to evaluate such tumor-agnostic
treatments. It is currently not clear to what extent tumor-
agnostic therapies will be implemented at the long term and,
also, whether they will be limited to a few drugs or extended to
a high number of agents. Part of the pathology community is
skeptical, based on the specificities of signaling pathway ac-
tivation regarding histological type and organ of origin. It is
evident, however, that pathologists should be ready to incor-
porate biomarker identification of these agnostic therapy-
related markers that will probably coexist in the future with tumor-specific predictive biomarkers. Even in this scenario, interpretation of molecular findings should be done in the setting of microscopical appearance and control of pre-analytical conditions.

Moreover, incorporation of somatic molecular testing integrated in pathology has a profound positive impact on attractiveness of pathology as a medical discipline in medical students who may decide to become pathologists. Furthermore, it has also important positive consequences in training and postgraduate education. The responsibility of incorporating molecular assays into routine pathology also requires deep understanding of the field by pathologists, not only for those directly involved in the workflow of the molecular tests.

An international strategy should be considered to give support to countries where molecular pathology is performed so far only in minimal extent, in order to face the scenario of increasing technological complexity and hardware requirements [25].

The issue of liquid biopsy (testing of circulating cell-free DNA released by the tumor—ctDNA) was not within the scope of this paper, which was exclusively focused on somatic molecular testing in tumor tissue. However, it is a very promising technique, regularly performed in many pathology departments across Europe. Although, at present, it is limited to a selected group of neoplasms such as lung cancer, its use will be probably extended also to other types of cancer in the near future.

Technical issues

Technical issues are important to obtain correct results [26–30]. Pathology departments are responsible for providing the appropriate pre-analytical conditions which are crucial to get correct results. The control of pre-analytical factors is included also in the ISO15189 standard, which is to be followed to fulfill all conditions important for quality control of pathology departments and molecular laboratories. In Europe, the technical specifications for pre-analytics, issued by CEN (European Committee for Standardization) (https://www.cen.eu), should be applied. These are then translated into ISO international standards after 1 or 2 years. Involvement of pathologists in the entire process of molecular analysis ensures optimization of pre-analytical variables, such as cold ischemia time and optimal fixation.

Quality control is a very important issue. Pathology departments should demonstrate to be capable to perform somatic molecular testing in optimal conditions, at all steps of the technical process at the pre-analytical, analytical, and post-analytical levels. External quality control by accredited agencies is required.

Cold ischemia time is the period between tissue surgical removal and fixation. It is an important factor, since DNA, RNA, and proteins are altered during such period, with a clear impact on the results of testing using molecular techniques [30]. Tissue samples submitted to inappropriate fixation (too short, too long, inadequate concentration of fixative, etc.) may also yield incorrect results. Moreover, there are different protocols for paraffin-embedding as well as variations in this process that can affect the quality of the nucleic acids within the tissues.

As mentioned before, selection of the appropriate tissue block for molecular analysis is crucial in the light of tumor heterogeneity [31]. It is important to guarantee the optimal absolute number of neoplastic cells, as well as to quantify percentage of neoplastic cells in relation to non-neoplastic elements, such as inflammatory infiltrate, fibroblasts, and other cells of the tumor stroma. Presence of necrosis may contribute to difficulties to get correct results. Necrotic areas should be excluded from testing. If this is not possible, the amount of necrosis has to be quantified. Macro- or micro-

![Workflow diagram of somatic molecular testing](image-url)
dissection is frequently necessary to ensure the best quality of the tumor fragment for molecular analysis, and this can only be done by individuals with expertise in pathology. Occasionally, the initially selected tumor tissue fragment does not fulfill criteria for quality control, which leads to repetition of the procedure and selection of another tissue sample. Sometimes, the tissue does not fulfill quality requirements for NGS, and material may be submitted to analysis by an alternative single-gene approach. This workflow should follow standardized protocols to ensure appropriate turnaround times. Taking all these factors into account, a close integration of molecular testing into routine workflow of pathology departments is very important to guarantee the shortest turnaround time for interpretation of the results. This may have an important impact on initiation of appropriate treatment, namely, in patients with advanced disease.

Conclusions

In this article, the importance of interpreting somatic molecular alterations of tumors in the light of morphology has been emphasized. A central role of pathology departments is necessary in the process of analysis and interpretation of somatic genomic alterations in cancer, not just as tissue providers for their interpretation outside this context. There are many reasons from the scientific, technical, and logistics points of view. The issue is important in terms of patient safety, since patients deserve clinically relevant interpretation of somatic alterations in cancer, being performed and interpreted under optimal conditions, quality control of the whole procedure, and optimal turnaround time.

Acknowledgments The proposal for this position paper was approved by the Publication Task Force of the European Society of Pathology (ESP), and this approval was subsequently verified by the Council of ESP. We thank Mar Varela, Dolors Cuevas, Ana Velasco and Jordi Temprana for help in writing the manuscript.

Author’s contribution Xavier Matias-Guiu wrote the initial draft of the manuscript which was subsequently edited by Giorgio Stanta, Fátima Cameiro, Ales Ryska, Gerald Hoefler, and Holger Moch. All authors have approved the manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558
2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
3. Patel SP, Schwaeerle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesiari S, Piciela DI, Hazenova LA, Helsten TL, Lippman SM, Parker BN, Kurzrock R (2015) Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget 6:32602–32609
4. Pena GP, de Andrade-Filho JS (2009) How does a pathologist make a diagnosis? Arch Pathol Lab Med 133:124–132
5. Srigley JR (2009) The pathologist as diagnostic oncologist. Pathology. 41:513–514
6. Walk EE (2009) The role of pathologists in the era of personalized medicine. Arch Pathol Lab Med. 133:605–610
7. Salto-Tellez M, James JA, Hamilton PW (2014) Molecular pathology - the value of an integrative approach. Mol Oncol 8:1163–1168
8. Parums DV (2016) The role of pathologist in the era of personalized medicine. SM J Clin Pathol 1:1003
9. Rodriguez-Canales J, Eberle FC, Jaffe ES, Emmert-Buck MR (2011) Why is it crucial to reintegrate pathology into cancer research? Bioessays. 33:490–498
10. Ince TA, Ward JM, Vali VE, Sgroi D, Nikitin AY, Loda M, Griffler SM, Crum CP, Crawford JM, Bronson RT, Cardiff RD (2008) Do-it-yourself (DIY) pathology. Nat Biotechnol 26:978–979
11. Horlings HM, Shah SP, Huntsman DG (2015) Using somatic mutations to guide treatment decisions: context matters. JAMA Oncol 1:275–276
12. Schneider G, Schmidt-Suppriam M, Rad R, Saur D (2017) Tissue-specific tumorigenesis: context matters. Nat Rev Cancer 17:239–253
13. Sieber OM, Tomlinson SR, Tomlinson IP (2005) Tissue, cell and stage specificity of (epi)mutations in cancers. Nat Rev Cancer 5:649–655
14. Schaefer MH, Serrano L (2016) Cell type-specific properties and environment shape tissue specificity of cancer genes. Sci Rep 6:20707
15. Chandarlapaty S (2012) Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov 2:311–319
16. Dubbink HJ, Deans ZC, Tops BB, van Kemenade FJ, Koljenović S, van Krieken HJ, Blokx WA, Djinjens WN, Groenen PJ (2014) Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe. Mol Oncol 8:830–839
17. Bosman FT (2018) Tumor heterogeneity: will it change what pathologists do? Pathobiology. 85:18–22
18. Venkatesan S, Swanton C (2016) Tumor evolutionary principles: how Intratumor heterogeneity influences Cancer treatment and outcome. Am Soc Clin Oncol Educ Book 35:e141–e149
19. Griffin J, Treanor D (2017) Digital pathology in clinical use: where are we now and what is holding us back? Histopathology. 70:134–145
20. Niazi MKK, Parwani AV, Gurcan MN (2019) Digital pathology and artificial intelligence. Lancet Oncol 20:e253–e261

© Springer
21. Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elimberger G, Kerr K, López-Rios F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E (2016) Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch 469:489–503

22. Garber K (2018) Tissue-agnostic cancer drug pipeline grows, despite doubts. Nat Rev Drug Discov 17:227–229

23. Coccol E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731–747

24. Penault-Llorca F, Rudzinski ER, Sepulveda AR (2019) Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol 72:460–467

25. Ryška A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, Kovalszyk I, Olszewski W, Oz B, Plank L, Timar J (2018) NSCLC molecular testing in Central and Eastern European countries. BMC Cancer 18:269

26. Hicks DG, Boyce BF (2012) The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research. Biotech Histochem 87:14–17

27. Compton CC, Robb JA, Anderson MW, Berry AB, Birdsong GG, Bloom KJ, Branton PA, Crothers JW, Cushman-Vokoun AM, Hicks DG, Khoury JD, Laser J, Marshall CB, Misialek MJ, Natale KE, Nowak JA, Olson D, Pfeifer JD, Schade A, Vance GH, Walk EE, Yoh SL (2019) Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine. Arch Pathol Lab Med 143:1346–1363

28. de Jong D, Verbeke S, Meijer D, Hogendoorn PC, Bovee JV, Szuha K (2011) Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples. BMC Res Notes 4:1

29. Groenen PJ, Blomxa WA, Diepenbroek C, Burgers L, Visinoni F, Wesselin P, van Krieken JH (2011) Preparing pathology for personalized medicine: possibilities for improvement of the preanalytical phase. Histopathology. 59:1–7

30. Dotti I, Bonin S, Basili G, Nardon E, Balani A, Siracusano S, Zanconati F, Palmisano S, De Manzini N, Stanta G (2010) Effects of formalin, methacarn, and fineFIX fixatives on RNA preservation. Diagn Mol Pathol 19:112–122

31. Hemmoller E, Renke B, Beyser K, Dietmaier W, Langner C, Rüschoff J (2001) Piffalls in diagnostic molecular pathology—significance of sampling error. Virchows Arch 439:504–511

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.